DGX
A small but meaningful tune-up
Quest Diagnostics is back with a fresher map for 2026, and it’s pointing a bit higher than before. The company now expects adjusted diluted EPS of $10.63 to $10.83, up from a prior range of $10.50 to $10.70.
Revenue got a bump too
Net revenues are now projected at $11.78 billion to $11.90 billion, also higher than the earlier outlook. That’s not exactly “call your friends” level fireworks, but it is the sort of guidance raise investors like to see when they’re trying to figure out whether a healthcare name is humming along or just coasting.
Why you should care
Guidance hikes can matter more than a flashy headline because they tell you what management thinks the next stretch of the road looks like. If Quest is seeing stronger demand, better pricing, or smoother operations, that can support the stock even without a dramatic earnings surprise.
The bigger picture
Quest isn’t a meme-stock roller coaster. It’s more of a steady-as-she-goes business where incremental changes in guidance can signal real operational momentum. Big picture: when a company quietly raises the bar on both profits and sales, that usually beats the alternative.